British Columbia Drug and Poison Information Centre (BC DPIC)
Healthcare Professionals
Health Headlines
Weblinks
About DPIC
Contact
Index
Log in
Search this site:
Poison Information
24-Hour Line:
1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
General Information
Prevention Tips
Prevention Material
Fact Sheets
BC Poison Control
Springtime Hazards
Holiday Hazards
Poison FAQ
Antidote Stocking Guidelines
UPDATED
Opioid Guidelines
Poison Management Manual
Drug Information
Drug Information Line
for BC Healthcare Professionals Only
1-866-298-5909 or
604-707-2787
(Mon - Fri, 9am to 4pm)
Clinical Practice Guidelines
Drug Product Listings
Safe Medication Use
Adverse Reaction Reporting
DI Perspectives Newsletter
Drug Desk Newsletter
Home
›
Drug Product Listings
› Cemiplimab
Cemiplimab
Trade Name:
Libtayo
Manufacturer/Distributor:
Sanofi-aventis Canada Inc.
Classification:
Antineoplastic agent
Monoclonal antibody
ATC Class:
L01XC33 - cemiplimab
Status:
active
Notice of Compliance (yyyy/mm/dd):
2019/04/10 (NOC/C)
Date Marketed in Canada (yyyy/mm/dd):
2019/05/24
Presentation:
Injection: 250 mg/5 mL. DIN: 02487152
Injection: 350 mg/7 mL. DIN: 02487144
Comments:
For treatment of adults with squamous call carcinoma. NOC/C issued pending results of trials to verify clinical benefit.
Back to:
Drug Product Listings
-
A
+
A
Follow DPIC
Facebook
Twitter
Take the DPIC Caller Satisfaction Survey